Trial Profile

Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms Cyto-KIK

Most Recent Events

25 Apr 2025 Planned End Date changed from 1 Feb 2027 to 1 Feb 2028.
25 Apr 2025 Planned primary completion date changed from 1 May 2026 to 1 May 2027.
01 May 2023 Results(n=16) assessing Surgical Complications in Patients with Metastatic Clear Cell Renal Cell Carcinoma Receiving Perioperative Cabozantinib and Nivolumab presented at the 118th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com